Bleakley Financial Group LLC Has $722,000 Stock Holdings in Organon & Co. (NYSE:OGN)

Bleakley Financial Group LLC boosted its position in Organon & Co. (NYSE:OGN) by 302.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 48,372 shares of the company’s stock after buying an additional 36,367 shares during the quarter. Bleakley Financial Group LLC’s holdings in Organon & Co. were worth $722,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in OGN. Pacer Advisors Inc. boosted its stake in shares of Organon & Co. by 94,482.1% in the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after purchasing an additional 11,140,388 shares during the last quarter. Geode Capital Management LLC grew its holdings in Organon & Co. by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock worth $81,288,000 after acquiring an additional 82,220 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Organon & Co. by 35.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock valued at $63,570,000 after acquiring an additional 875,128 shares during the last quarter. Thompson Siegel & Walmsley LLC raised its position in shares of Organon & Co. by 6.4% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 2,262,379 shares of the company’s stock valued at $43,279,000 after acquiring an additional 136,457 shares during the last quarter. Finally, Private Management Group Inc. lifted its stake in shares of Organon & Co. by 11.9% in the 4th quarter. Private Management Group Inc. now owns 2,119,288 shares of the company’s stock valued at $31,620,000 after purchasing an additional 225,420 shares during the period. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Stock Down 1.7 %

NYSE:OGN opened at $14.63 on Monday. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The stock has a 50-day moving average price of $15.37 and a two-hundred day moving average price of $17.66. The stock has a market cap of $3.77 billion, a price-to-earnings ratio of 2.90, a PEG ratio of 0.83 and a beta of 0.76. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Analyst Upgrades and Downgrades

Separately, TD Cowen raised Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $21.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.